An observational study in Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 and Anatomic Stage IB Breast Cancer AJCC v8, sponsored by University of Southern California. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by University of Southern California · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,447 studies in Brain Neoplasms with a site in United States — 233 open to participants now, 355 under way, 18 of them phase 3. Brain Neoplasms · United States.
Among the 1,447 studies in Brain Neoplasms with a site in United States, this one is the 58th largest by enrollment of the 191 observational ones that give a count, is one of 46 that started in 2021, is one of 193 observational ones, reaches primary completion later than 64 of the 353 other live ones, and was the 1,203rd registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →233 of the 1,447 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Brian J.Gill · Sites in United States
Ages 22–65
Stanford University · Sites in United States
Ages 6 mo–25 yrs
University of California, San Francisco · Sites in United States
Ages 18+
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
University of Florida · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 39 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,447 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 554 · Phase 2 522 · Phase 3 72 · Phase 4 18
First in 1979; this study’s year is marked. 46 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 173 is above the median of 99 across 433 observational studies indexed under Brain Neoplasms.
Median enrollment 30 across the 1,192 interventional studies, 76 across the 191 observational. Of the 994 that completed or were terminated, 355 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
221 of 1,447 have an industry lead sponsor. The 10 most frequent:
University of Southern California is the lead sponsor of 793 studies on the registry; 138 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 32 (45%) have results posted.
University of Southern California has 7 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
140 of the studies in Brain Neoplasms with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT03741673Phase 3M.D. Anderson Cancer CenterPre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases | 2027-01-31 |
| NCT05438212Phase 3NRG OncologyComparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases | 2027-03-16 |
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT00950001Phase 3M.D. Anderson Cancer CenterStereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases | 2027-04-30 |
Add all 140 to your calendar (.ics) → With an account.
Among the 1,447 studies in Brain Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This longitudinal observational study examines how social health, including social support, social roles, loneliness, social anxiety, and social network characteristics, relates to physical activity, sedentary time, and quality of life among ethnically and racially diverse adolescent and young adult (AYA) cancer patients aged 18-39 years. The study follows participants over four clinically significant timepoints in the first 12 months after diagnosis (baseline near diagnosis, mid treatment, near end of treatment, and 12 month follow up). At each timepoint, patients complete questionnaires and wear a wrist worn accelerometer for one week.
PRIMARY OBJECTIVES:
I. Characterize trajectories of social health over the course of cancer treatment and into early survivorship; II. Investigate longitudinal and potentially reciprocal associations between social health and activity behaviors (physical activity and sedentary time) and their relationship to quality of life; III. Examine whether gender, race/ethnicity, socioeconomic status, and symptom burden moderate these associations.
OUTLINE:
Patients complete surveys over 40 minutes and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
This study's enrollment of 173 is above the median of 99 across 433 observational studies indexed under Brain Neoplasms.
Browse Brain Neoplasms studies →University of Southern California is the lead sponsor of 793 studies on the registry; 138 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 32 (45%) have results posted.
Compared within Brain Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Central Nervous System Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients diagnosed and/or treated with cancer between ages 18-39 at University of Southern California (USC) hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients complete surveys and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months.
Other: Medical Device Usage and Evaluation · Other: Quality-of-Life Assessment · Other: Survey Administration
Wear an actigraph GT3X-BT accelerometer
Complete survey
Also known as: Quality of Life Assessment
Complete survey
Change in social role functioning
Assessed using the PROMIS Ability to Participate in Social Roles and Activities Short Form 4a, which measures limitations in participation in usual social roles and activities due to health (higher scores indicate better participation).
Time frame: Baseline up to 1 year
Change in perceived emotional support
Assessed using the PROMIS Emotional Support Short Form 4a, which measures perceived availability of people who provide emotional support, such as care, understanding, and someone to listen (higher scores indicate more emotional support).
Time frame: Baseline up to 1 year
Change in perceived informational support
Assessed using the PROMIS Informational Support Short Form 4a, which measures perceived availability of people who provide advice, information, and guidance (higher scores indicate more informational support).
Time frame: Baseline up to 1 year
Change in perceived instrumental support
Assessed using the PROMIS Instrumental Support Short Form 4a, which measures perceived availability of people who provide practical help and assistance with tasks (higher scores indicate more instrumental support).
Time frame: Baseline up to 1 year
Change in loneliness score
Assessed using the UCLA Loneliness Scale short form, which measures subjective feelings of loneliness and social disconnection (higher scores indicate greater loneliness).
Time frame: Baseline up to 1 year
Change in social anxiety symptoms
Assessed using the Mini Social Phobia Inventory (Mini SPIN), a brief validated measure of social anxiety and fear of social interactions (higher scores indicate greater social anxiety).
Time frame: Baseline up to 1 year
Change in social network density
Assessed using a study developed egocentric social network questionnaire in which participants list up to 10 important adult social contacts and indicate which contacts know each other; density is calculated as the proportion of possible ties that are present (higher values indicate a more densely connected network).
Time frame: Baseline up to 1 year
Change in proportion of supportive social ties
Assessed using a study developed egocentric social network questionnaire that measures whether each named social contact provides social support and encouragement for physical activity; the outcome is the proportion of social ties providing support (higher values indicate a more supportive network).
Time frame: Baseline up to 1 year
Change in frequency of social contact
Assessed using a study developed egocentric social network questionnaire that captures how often participants interact with each named social contact; the outcome is the average reported frequency of contact across alters (higher values indicate more frequent social contact).
Time frame: Baseline up to 1 year
Change in total daily physical activity
Assessed using a wrist worn ActiGraph GT3X BT accelerometer worn for 7 consecutive days at each time point. Raw data are converted to monitor independent movement summary (MIMS) units, and total daily physical activity is represented by average daily MIMS units across valid wear days (higher values indicate more physical activity).
Time frame: Baseline up to 1 year
Change in total daily sedentary time
Assessed using a wrist worn ActiGraph GT3X BT accelerometer worn for 7 consecutive days at each time point. Sedentary time is calculated from accelerometer data as average minutes per day spent in sedentary behavior (e.g., low movement periods while awake) across valid wear days (higher values indicate more sedentary time).
Time frame: Baseline up to 1 year
Change in Quality of Life
Patient reported quality of life using Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health 10, assessed at baseline and 12 month follow up. This is a 10-item patient-reported questionnaire measuring general physical, mental, and social health. Most questions use a 1-to-5 point scale. Higher numerical values consistently represent better health or lower symptoms. The survey produces two separate scores: Global Physical Health (GPH) and Global Mental Health (GMH). Raw response values are summed and converted into standardized T-scores where a score of 50 represents the U.S. general population average (standard deviation of 10).
Time frame: Baseline up to 1 year
Symptom Burden
Symptom burden assessed using the MD Anderson Symptom Inventory (MDASI) at all four timepoints. This survey is a multi-symptom patient-reported outcome (PRO) measure used to assess the severity of symptoms experienced by patients with cancer and the interference with daily living caused by these symptoms.
Time frame: Baseline up to 1 year
Started Nov 2021 (actual). Primary completion is estimated for Dec 2026, 61 months after the start.
Of 182 non-industry observational studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 269. This study's planned 61 months is below that.
Counting every sponsor, half of 200 studies reached it within 82 months; a quarter within 41 and three quarters within 269.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Southern California →